Ben Cools is a Researcher affiliated with the Faculty of Medicine and Pharmacy at Vrije Universiteit Brussel (VUB), specializing in Pharmaceutical and Pharmacological Sciences . He holds a doctoral student position in In Vitro Toxicology and Dermato-Cosmetology. His work focuses on understanding hepatic responses to microgravity and space radiation, particularly in the context of non-alcoholic fatty liver disease (NAFLD) countermeasures for astronauts. Current projects include leading the FWOSB150 Project (2023-2027), investigating pannexin1 channels' role in NAFLD under microgravity and radiation conditions. He actively collaborates with the European Space Agency (ESA), presenting research at international forums like the Microphysiological Systems World Summit. Key contributions include groundbreaking work on spaceflight hepatotoxicity mechanisms and advocating for reduced animal testing in space research via 3Rs principles. His activities span 8 professional engagements (2023-2025), including organizing conferences and advising ESA's Pharmacological Countermeasures Team.
Ashley Brown is an Associate Professor of Biomedical Engineering at North Carolina State University's College of Engineering. She leads research focused on biomaterials, hemostasis, and regenerative medicine. Her work integrates material science with clinical applications, particularly in developing fibrin-based therapies for wound healing, thrombosis management, and infection control. Education details are not explicitly listed, but her research spans interdisciplinary areas including nanomedicine, tissue engineering, and immunomechanical systems. Key projects include designing synthetic platelet-like particles, fibrin-targeted nanogels, and microphysiological models for trauma and coagulation studies. Research interests emphasize fetal vs. adult fibrinogen differences, sialic acid effects on clotting kinetics, and biomaterial scaffolds for enhanced healing. Her lab develops innovative solutions for neonatal coagulopathies, antibiotic-resistant bacteria, and point-of-care diagnostics. Publications highlight advancements in fibrin-based drug delivery systems, antimicrobial materials, and microfluidic organ-on-a-chip models. Collaborations likely involve biomedical engineering, materials science, and clinical partners. Awards and grants include the NSF CAREER award for dynamic microgel research. Her work bridges fundamental science with translational applications addressing unmet clinical needs in hemostasis and trauma care.
Alexander Revzin, Ph.D., is a Professor of Biomedical Engineering at Mayo Clinic in Rochester, Minnesota, with a primary appointment as a Consultant in the Department of Physiology & Biomedical Engineering and a joint appointment in the Division of Gastroenterology and Hepatology, Department of Internal Medicine. He leads the Cellular Microsystems and Biosensors Laboratory, a multidisciplinary team developing microphysiological systems (organs-on-chip) to study liver fibrosis, stem cell biology, and biosensor applications. Department: Department of Physiology & Biomedical Engineering School: Mayo Clinic College of Medicine and Science Research Lab: Cellular Microsystems and Biosensors Laboratory Email: revzin.alexander@mayo.edu Dr. Revzin's research lies at the intersection of engineering and biology, with a focus on microfabrication, microfluidics, biosensors, and regenerative medicine. His lab develops innovative platforms for cell cultivation and analysis, including liver-on-chip devices, stem cell spheroid systems, and biosensors for inflammatory cytokines and metabolites. These tools aim to model liver injury, improve stem cell differentiation, and enable point-of-care diagnostics, particularly for infectious diseases and liver conditions. The 15 most recent publications (2023–2025) reflect a strong trend toward personalized medicine, organ-on-chip modeling, and biosensor integration. Key themes include microencapsulation of stem cell-derived tissues, microfluidic organoids for cancer therapy testing, extracellular vesicle analysis, and real-time monitoring of cellular function. His work spans high-impact journals in bioengineering, materials science, and translational medicine. Scientific awards and professional recognition include: Fellow, American Institute for Medical and Biological Engineering (AIMBE), 2015 Program Director, Nano-Biosensing, National Science Foundation, 2013–2014 Chancellor’s Fellow, University of California, 2012 Associate Editor, Microsystems & Nanoengineering (Nature group journal), 2014–present Dr. Revzin actively mentors a large team of researchers and students, with frequent co-authorship from lab members such as Gwon K, de Hoyos-Vega JM, Gonzalez-Suarez AM, and Stybayeva G. His lab is equipped for microfabrication, cell culture, and biosensor development, supporting both basic and translational research. While no explicit grant details are listed, his leadership in major journals and multi-institutional collaborations suggests strong funding support. The Cellular Microsystems and Biosensors Laboratory fosters interdisciplinary collaboration, integrating mechanical, chemical, and biomedical engineers with chemists and biologists to advance regenerative medicine and diagnostic technologies.
Joseph Wu is a Professor actively teaching advanced courses across Medicine (MED), Bioengineering (BIOE), Radiology (RAD), Immunology (IMMUNOL), and Stem Cell Biology and Regenerative Medicine (STEMREM) departments. His instructional portfolio spans undergraduate research (MED 199, RAD 199), graduate research (MED 399, STEMREM 399), directed studies (BIOE 391, MED 299), and specialized courses including MED 225: Introduction to Drug Development and IMMUNOL 290: Teaching in Immunology. His research focuses on: Cardiovascular Engineering through cardiac tissue modeling Stem Cell Biology using induced pluripotent stem cells (iPSCs) for disease modeling Drug Development pipelines for therapeutic innovation Cardiac Tissue Engineering of physiological models Cardiotoxicity Screening via AI-driven platforms like ADMET-AI Multi-organ disease modeling of cardiovascular-kidney-metabolic syndrome Analysis of his 2024-2025 publications reveals dominant trends in iPSC-based cardiac disease modeling, CRISPR screening for cardiotoxicity targets, and multi-organ-on-a-chip systems. His work bridges AI-driven drug screening with physiological tissue engineering to address cardiac fibrosis, arrhythmias, and cardiometabolic disorders. No scientific awards were documented in the provided materials. Professor Wu mentors students through extensive research channels: Undergraduate Research: MED 199, RAD 199, IMMUNOL 199, STEMREM 199 Graduate Research: MED 399, RAD 399, IMMUNOL 399, STEMREM 399, BIO 300X Directed Investigation: BIOE 392, MED 280, RAD 280, IMMUNOL 280 Advanced Laboratory: BIOE 191X, BIOE 191 No specific laboratory infrastructure or collaborative teams were described in the source materials.
George A. Truskey is the R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering at the Pratt School of Engineering, Duke University . He has held this position since 2011 and previously served as Professor of Biomedical Engineering (2000–present) and held leadership roles including Senior Associate Dean for Research (2011–2014) and Chair of the Department of Biomedical Engineering (2003–2011). Education : Ph.D. from Massachusetts Institute of Technology (1985), B.S.E. from University of Pennsylvania (1979). His research focuses on cardiovascular tissue engineering, mechanisms of atherogenesis, cell adhesion, and cell biomechanics. He develops microphysiological systems to study vascular and skeletal muscle diseases, including Progeria and rheumatoid arthritis, with applications in drug toxicity testing and disease modeling. Recent publications highlight work on vascular aging in chronic kidney disease, heterocellular muscle engineering, and biomimetic blood vessel fabrication. Grants include NIH funding for pediatric therapeutics (2025–2030), skeletal muscle research (2024–2029), and microphysiological systems (2024–2028). Scientific Awards : AAAS Fellow (2014) BMES Distinguished Service Award (2012) Capers and Marion McDonald Award (2007) NIH CSR College of Reviewers (2010) He has advised numerous grants, including NIH-funded projects on engineered tissues and vascular disease models. His lab ( Truskey Lab ) collaborates with institutions like the American Heart Association and International Foundation for Ethical Research.
Dr. Linette Willemsen serves as an Associate Professor in the Pharmacology department within the Faculty of Science at Utrecht University. Her research program focuses on Mucosal Immunology and Pharma & Nutrition, with particular emphasis on dietary components' role in immune health. She maintains active laboratory operations at the David de Wiedgebouw building (Universiteitsweg 99, Utrecht) and collaborates extensively with immunology and nutrition research groups. Her primary research interests center on mechanisms by which dietary components—particularly fermentable fibers, bacterial fermentation products, and n-3 long-chain polyunsaturated fatty acids—modulate immune responses to prevent non-communicable immune disorders like food allergy and asthma. Development of advanced mucosal immune co-culture models mimicking allergic sensitization cascades Investigation of human milk oligosaccharides' immunomodulatory effects on epithelial-immune crosstalk Exploration of how non-digestible oligosaccharides enhance defense against viral/bacterial challenges Translational studies on dietary components as adjunct therapy for chronic inflammatory disorders Her work bridges fundamental immunology with nutritional science to identify clinically relevant interventions. Analysis of her 15 most recent publications reveals consistent focus on mucosal immune modeling (73% of articles), food allergy mechanisms (67%), and nutritional immunomodulation (80%). Key methodological trends include sophisticated co-culture systems (87%), human-derived cell models (73%), and prebiotic intervention studies (60%). The research demonstrates progressive integration of organ-on-chip technology (27% of recent work) and nanoparticle delivery systems (20%) for therapeutic applications. Her collaborative network spans multiple institutions, with frequent co-authorship with Garssen, Folkerts, and Willemsen research groups. Current projects appear supported by Dutch national research grants focused on food allergy prevention and mucosal immunology, though specific funding sources aren't detailed in the provided materials. Ongoing work includes developing sequential mucosal models for predicting food allergenicity and testing dietary interventions for barrier protection.
Dr. Samuel Arnold is an Assistant Professor in the Department of Pharmaceutics at the University of Washington School of Pharmacy, where he joined in 2023. His research focuses on characterizing exposure-response relationships for therapeutic treatment of infectious diarrhea, particularly for pathogens like Cryptosporidium and Shigella. As a member of the Bill & Melinda Gates Foundation Cryptosporidium Drug Accelerator (CryptoDA), Dr. Arnold has led significant efforts to identify pharmacokinetic/pharmacodynamic relationships for anti-cryptosporidiosis drugs. Dr. Arnold earned his Bachelor of Science in Biochemistry from the University of Colorado and his Ph.D. in Pharmaceutics from the University of Washington. His research interests center on infectious diseases, particularly pharmacokinetic-pharmacodynamic modeling for treatment of enteric infections, enteric disease induced changes in drug disposition, and improved preclinical models of drug disposition in the gastrointestinal tract. His expertise spans drug discovery, in vitro to in vivo extrapolation, intestinal surgery and GI diseases, microphysiological organ systems, pharmacokinetics-pharmacodynamics, pharmacology, simulation modeling, and translational research. Dr. Arnold's publication record demonstrates significant contributions to the understanding of diarrheal diseases and their impact on drug pharmacokinetics. His work shows a clear progression from foundational studies on parasitic infections to clinical applications, with a strong emphasis on translational research that bridges laboratory findings with clinical practice. Recent publications highlight his focus on physiologically based pharmacokinetic modeling to predict how diarrheal diseases affect oral drug pharmacokinetics, as well as ongoing clinical investigations into novel treatments for shigellosis and cryptosporidiosis. Dr. Arnold actively participates in collaborative research initiatives, including clinical trials investigating clofazimine as a potential anti-cryptosporidiosis treatment (Clinicaltrials.gov #NCT03341767). His lab is working on developing pharmacokinetic models that can predict the impact of diarrhea on drug exposure prior to human dosing, which represents a significant advancement in the field of infectious disease pharmacology. Dr. Arnold accepts students to his laboratory and teaches courses PCEUT531, PCEUT532, and PCEUT506 at the University of Washington School of Pharmacy. His research has important implications for global health, as diarrheal diseases remain the second leading cause of death in children under five years old worldwide.
Peta Clode is an Associate Professor at The University of Western Australia (UWA), affiliated with the Centre for Microscopy, Characterisation & Analysis and the UWA Oceans Institute. She holds roles such as Platform Leader for Biosciences Electron Microscopy and WA Representative for CryOz. Her research focuses on cellular imaging, biomineralization, nutrient transport, and symbiotic systems across plant, animal, and microbial systems. Education: PhD from La Trobe University (2002), supported by an APA Scholarship. Academic career progression: Lecturer (UWA, 2003–2007), Senior Lecturer (2007–2015), and Associate Professor (2015–present). Research emphasizes biological microanalysis using techniques like Secondary Ion Mass Spectrometry (SIMS), electron microscopy, and elemental analysis. Current projects include nutrient dynamics in rhizospheres, crop tolerance to calcium/phosphorus stresses, and applications of high-intensity focused ultrasound in dentistry. She also investigates biomineralization in marine organisms and environmental adaptations of plants. Teaching includes courses like Materials Characterisation for Bioengineering (SCIE5516) and Advanced Techniques in Molecular Sciences (MSCI4006). She coordinates microscopy training programs (SEM/M, TEM/M) at the CMCA. Grants include projects on laser ablation, phosphorus cycling in legumes, and ultrasound dental applications. Collaborations span marine biology, environmental science, and biomedical engineering, contributing to UN SDGs like Oceans and Sustainable Agriculture. Labs/teams: Leads microscopy platforms and collaborates with institutions globally on projects like coral resilience and Cryptosporidium modeling. Her work bridges fundamental biology with applied solutions in agriculture and healthcare.
Kulwinder Kaur is a Lecturer in the School of Pharmacy and Biomolecular Sciences at the Royal College of Surgeons in Ireland (RCSI). Her academic journey includes a PhD from Guru Nanak Dev University (2012–2017) and postdoctoral roles at RCSI (2020–2023) and the Indian Institute of Technology Delhi (2017–2019). She specializes in bioengineering, biomaterials, and tissue engineering, with a focus on regenerative medicine and cancer therapy. Her research addresses bone regeneration, injectable hydrogels, and 3D disease models. Research Interests: Her work spans Design of biomaterials for bone repair (e.g., chitosan/collagen hydrogels, silk fibroin composites) 3D bioengineered models for breast cancer and microbiota-gut-brain axis studies Nano-engineered hydrogels for minimally invasive treatments Gamma ray shielding materials for biomedical applications Grants & Projects: "NanoDOT: Nano-Engineered Biomaterial Delivery System with Controlled Strontium Release" (Science Foundation Ireland, 2023–2027) "Injectable Chitosan/Collagen Hydrogels for Bone Repair" (European Research Council, 2022–2023) "Hydroxyapatite Bioceramics" (Department of Science & Technology, India, 2014–2017) Labs & Collaborations: Her research integrates interdisciplinary teams focusing on biomaterials, regenerative medicine, and cancer biology. She collaborates with institutions like IIT Delhi and contributes to RCSI’s Biomaterials & Pharmaceuticals Sciences cluster.
Leo Wan is a Professor of Biomedical Engineering at Rensselaer Polytechnic Institute (RPI), where he has served since 2011 after completing his Ph.D. at Columbia University. His research program focuses on developing innovative tissue regeneration strategies and organ-on-a-chip platforms for disease modeling and drug screening, operating at the intersection of engineering and life sciences. His educational background includes: Ph.D. in Biomedical Engineering, Columbia University (2007) M.Eng. in Fluid Mechanics, University of Science and Technology of China (2001) B.S. in Theoretical and Applied Mechanics, University of Science and Technology of China (1998) Dr. Wan's research centers on tissue engineering and morphogenesis , with particular emphasis on cell chirality —a fundamental property governing left-right asymmetry in biological systems. His laboratory develops organ-on-a-chip devices using micro-/nanofabrication techniques to model cardiac development and disease, while investigating how biomechanical forces influence stem cell differentiation and tissue formation. Current projects explore chiral morphogenesis in vascular systems and its implications for congenital heart defects. Analysis of his recent publications (2022-2025) reveals a consistent focus on cellular chirality mechanisms in cardiovascular development, with increasing emphasis on biomechanical modeling and organ-on-a-chip translation . His work bridges fundamental biophysics with clinical applications, particularly in cardiac tissue engineering and cancer metastasis modeling. Major recognitions include: Fellow of the American Heart Association (2021) NIH Director's New Innovator Award (2014) Pew Scholar in Biomedical Sciences (2013) National Science Foundation CAREER Award (2013) Basil O'Connor Starter Scholar Award (March of Dimes, 2014) Dr. Wan has secured substantial research funding from NIH, NSF, and the American Heart Association to support his work on tissue regeneration and disease modeling. As principal investigator of the Wan Lab, he directs interdisciplinary research involving graduate students and postdoctoral fellows, with recent projects focusing on helical vasculogenesis and chiral cytotoxicity assays. His laboratory maintains active collaborations with the Center for Biotechnology and Interdisciplinary Studies (CBIS) and Center for Modeling, Simulation and Imaging in Medicine (CEMSIM) at RPI. The Wan Lab operates within RPI's Center for Biotechnology and Interdisciplinary Studies, utilizing advanced microfabrication facilities and stem cell culture resources. Current research teams are developing next-generation organ-on-a-chip platforms that integrate patient-derived cells for personalized drug testing, with particular focus on cardiac applications and tumor-vascular interactions.
Dr. Derek Boeldt is an Assistant Professor in the Department of Obstetrics and Gynecology at the University of Wisconsin-Madison. He holds a BSc (2005) and PhD (2013) from the same institution. His research focuses on translational approaches for preeclampsia therapy, emphasizing cell signaling targets downstream of abnormal hormonal inputs. Key interests include vascular biology adaptations during pregnancy and their disruption in preeclampsia. Education: BSc, University of Wisconsin-Madison (2005) PhD, University of Wisconsin-Madison (2013) Research Interests: Endothelial dysfunction mechanisms in preeclampsia Role of fatty acids and metabolites in pregnancy outcomes Inflammatory mediator effects on vascular health Therapeutic potential of conjugated linoleic acid (CLA) Recent Work Trends: His publications highlight immune cell interactions with endothelium, cytokine signaling pathways, and the protective role of CLA in maintaining vascular integrity. Recent studies (2023–2024) emphasize microphysiological systems to model disease mechanisms. Advising: Past advisees include Aishwarya Rengarajan and Amanda Mauro. He is a T32 Faculty Trainer in the ERP Program since 2016.
Prof. Dr. Volker Busskamp holds the professorship for Degenerative Retinal Diseases at the University of Bonn's Department of Ophthalmology. His interdisciplinary research combines stem cell biology, neural engineering, and optogenetics to develop vision restoration strategies. Major innovations include transcription factor-based photoreceptor programming, holographic optogenetics for neural circuit analysis, and organoid models for retinal degeneration. His laboratory develops microphysiological systems to study neuronal networks under altered gravity conditions in collaboration with the German Aerospace Center. Awarded the Paul Ehrlich and Ludwig Darmstaedter Junior Award and ERC Starting Grant, Dr. Busskamp's patented technologies advance therapeutic approaches for inherited retinal diseases.
Anna Grosberg, Ph.D., is an Associate Professor and Core Lab Faculty Director in the Department of Biomedical Engineering at the University of California, Irvine (UCI). She leads the Cardiovascular Modeling Laboratory, part of the UCI Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center (CIRC). Her work focuses on integrating computational modeling and tissue engineering to study cardiac development, function, and disease mechanisms, particularly leveraging stem cell-derived cardiomyocytes and in vitro/in silico models. Her research interests include multiscale modeling of cardiac structure-function relationships, mechanobiology of cardiac tissue, and translational applications in regenerative medicine. Key topics involve hypoxia effects in obstructive sleep apnea, genetic cardiomyopathies (e.g., LMNA mutations), and the biophysical basis of cardiac contractility. Collaborations span engineering, medicine, and industry to develop tools for drug discovery, medical devices, and personalized treatments. Dr. Grosberg has pioneered platforms like the 'Heart on a Chip' and developed quantitative methods for assessing cytoskeletal changes in diseases such as lung cancer and muscular dystrophy. Her educational contributions include the CardioStart program, a virtual tissue engineering course for high school students. Her lab emphasizes interdisciplinary innovation, combining experimental assays with advanced modeling to address cardiac disease at cellular, tissue, and organ levels. Current projects explore how mechanical forces influence myogenesis, the role of microtubules in muscle fiber integrity, and predictive models for OSA severity assessment.
Dmitry Markov is a Research Professor of Biomedical Engineering at Vanderbilt University's School of Engineering. His research focuses on developing microphysiological systems and organ-on-a-chip technologies to model tissue microenvironments ex vivo. These systems utilize microfluidic bioreactors for studying disease progression, drug efficacy, and environmental toxin effects. Markov's work integrates engineering principles with biological systems, emphasizing instrumentation for micro-scale measurements and environmental control within bioreactors. Education includes a Ph.D. and M.S. in Electrical Engineering from Texas Tech University, providing foundational expertise in microfluidics and sensor technologies. His interdisciplinary research bridges material science, computational modeling, and clinical applications, with a focus on PDMS-based device design and toxicokinetic analysis. Key research interests include optimizing organ-on-chip systems for personalized medicine, modeling tumor microenvironments, and developing integrated multi-organ platforms. His recent work explores metabolic dysfunction in neurological disorders using organ-on-a-chip models and investigates chemical-partitioning dynamics in biomaterials. Markov has contributed to advancing microfluidic valve and pump technologies, with patents covering rotary valves, capacitive pumps, and stackable bioreactor architectures. His lab develops both hardware innovations and computational models to enhance predictive toxicology and translational biomedical research.
Peter Gennemark is an Adjunct Associate Professor and Docent at the Department of Biomedical Engineering (IMT), Division of Biomedical Engineering (MT), Linköping University, with a strong collaborative role in systems pharmacology. He is also a Principal Scientist at AstraZeneca, Gothenburg, Sweden, where he contributes to industrial pharmaceutical research. His academic and industrial work is centered on mathematical modelling to understand diabetes and cardiovascular disease mechanisms and therapies. Institution: Linköping University Department: Department of Biomedical Engineering (IMT) Division: Division of Biomedical Engineering (MT) Industry Role: Principal Scientist, AstraZeneca Collaborator: Gunnar Cedersund (IMT) His research lies at the intersection of biomedical engineering and systems pharmacology, focusing on mathematical modelling to unravel biological mechanisms in diabetes and cardiovascular diseases . He contributes to knowledge-driven drug development, particularly in understanding disease progression and drug intervention effects. His work combines experimental data with computational models to support clinical tool and drug development. The recent publications (2024–2025) demonstrate a strong trend in systems pharmacology , drug delivery , and microphysiological systems . Topics include siRNA delivery, antisense oligonucleotide pharmacokinetics, 3D cell models, glucose homeostasis, and liver steatosis dynamics. These works reflect a consistent focus on quantitative, model-driven approaches in drug development and disease understanding, spanning molecular, cellular, and organ-level systems. Peter Gennemark is involved in a VR Medicine-funded project on Knowledge Driven Drug Development in collaboration with AstraZeneca. While no specific grants or students are listed, his role as a principal scientist and adjunct faculty suggests active involvement in research leadership and interdisciplinary advising. His work bridges academia and industry, contributing to both scientific advancement and pharmaceutical innovation. His research is conducted within the Division of Biomedical Engineering at Linköping University, a national hub for biomedical research and education. He is part of a collaborative team working on systems biology and pharmacological modelling, particularly with Gunnar Cedersund. The lab environment emphasizes interdisciplinary integration of mathematical models, biological data, and pharmaceutical applications.
